Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Sintilimab in Triple Negative Breast Cancer: NCT07394387 Clinical Landscape Report 2026
18 September 2026
NCT07394387 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tovecimig in Recurrent Glioblastoma: NCT07392957 Clinical Landscape Report 2026
18 September 2026
NCT07392957 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in ER-positive/HER2-negative Breast Cancer: NCT07408089 Clinical Landscape Report 2026
18 September 2026
NCT07408089 clinical landscape for ER-positive/HER2-negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Zimberelimab in Renal Cell Carcinoma: NCT07397611 Clinical Landscape Report 2026
18 September 2026
NCT07397611 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Sarcoma: NCT07410676 Clinical Landscape Report 2026
18 September 2026
NCT07410676 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19-CAR novel oncolytic vaccinia virus(The Second Affiliated Hospital Zhejiang University) in Indolent B-Cell Non-Hodgkin Lymphoma: NCT07398963 Clinical Landscape Report 2026
18 September 2026
NCT07398963 clinical landscape for Indolent B-Cell Non-Hodgkin Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Lisaftoclax in Diffuse Large B-Cell Lymphoma: NCT07398638 Clinical Landscape Report 2026
18 September 2026
NCT07398638 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Renal Cell Carcinoma: NCT07401875 Clinical Landscape Report 2026
18 September 2026
NCT07401875 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trastuzumab in Residual Neoplasm: NCT07407920 Clinical Landscape Report 2026
18 September 2026
NCT07407920 clinical landscape for Residual Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Ovarian Cancer: NCT07407452 Clinical Landscape Report 2026
18 September 2026
NCT07407452 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Polatuzumab Vedotin-Piiq in Diffuse Large B-Cell Lymphoma: NCT07415980 Clinical Landscape Report 2026
18 September 2026
NCT07415980 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fianlimab/Cemiplimab in Urothelial Carcinoma of the Urinary Bladder: NCT07414992 Clinical Landscape Report 2026
18 September 2026
NCT07414992 clinical landscape for Urothelial Carcinoma of the Urinary Bladder: endpoints, sponsor, phase, geography, readouts, asset context and development…